Hetero gets DCGI nod to launch Remdesivir for Covid-19 treatment
Posted by
www.biotecnika.org
Hetero will produce and launch the first generic Remdesivir under
Covifor brand in India following positive clinical outcomes under a
licensing agreement with Gilead Sciences Inc to expand access to
Covid-19 treatment in low and middle-income economies.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/hetero-gets-dcgi-nod-to-launch-remdesivir-for-covid-19-treatment/articleshow/76490670.cms
Subscribe to:
Post Comments (Atom)
Post a Comment